Seeking Alpha

Revance Therapeutics soars following IPO

  • After pricing its 6M-share IPO at $16, Revance Therapeutics (RVNC) opened at $21 and is now at $26.25, up 64%.
  • The developer of novel botox products currently has a market cap of $465M.
  • Prospectus, IPO preview
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)